Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,011
archived clinical trials in
Postmenopausal Syndrome

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Philadelphia Clinical Research
mi
from
Philadelphia, PA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Philadelphia Clinical Research
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Clinical Trials Research Services, LLC
mi
from
Pittsburgh, PA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Clinical Trials Research Services, LLC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Susan L Floyd, MD, PC
mi
from
Wexford, PA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Susan L Floyd, MD, PC
mi
from
Wexford, PA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Partners in Clinical Research, LLC
mi
from
Cumberland, RI
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Partners in Clinical Research, LLC
mi
from
Cumberland, RI
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Coastal Carolina Research Center
mi
from
Mt. Pleasant, SC
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Coastal Carolina Research Center
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Chattanooga Medical Research, LLC
mi
from
Chattanooga, TN
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Chattanooga Medical Research, LLC
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Access Clinical Trials
mi
from
Nashville, TN
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Access Clinical Trials
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Tekton Research
mi
from
Austin, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
DiscoveResearch, Inc.
mi
from
Bryan, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
DiscoveResearch, Inc.
mi
from
Bryan, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Advances In Health, Inc.
mi
from
Houston, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Advances In Health, Inc.
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
The Woman's Hospital of Texas Clinical Research Center
mi
from
Houston, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
The Woman's Hospital of Texas Clinical Research Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Research Across America
mi
from
Katy, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Research Across America
mi
from
Katy, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Radiant Research, Inc
mi
from
San Antonio, TX
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Radiant Research, Inc
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Virginia Women's Center
mi
from
Richmond, VA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Virginia Women's Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
National Clinical Research, Inc.
mi
from
Richmond, VA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
National Clinical Research, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Tidewater Clinical Research Inc
mi
from
Virginia Beach, VA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Tidewater Clinical Research Inc
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Women's Clinical Research Center
mi
from
Seattle, WA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Women's Clinical Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
North Spokane Women's Clinic Research
mi
from
Spokane, WA
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
North Spokane Women's Clinic Research
mi
from
Spokane, WA
Click here to add this to my saved trials
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
Evaluation of Pharmacokinetics of Paroxetine Following Single and Repeat Oral Administration of Mesafem (7.5 mg Paroxetine Mesylate) Capsules in Healthy Postmenopausal Women
Status: Enrolling
Updated:  10/14/2015
SNBL Clinical Pharmacology Center
mi
from
Baltimore, MD
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
Evaluation of Pharmacokinetics of Paroxetine Following Single and Repeat Oral Administration of Mesafem (7.5 mg Paroxetine Mesylate) Capsules in Healthy Postmenopausal Women
Status: Enrolling
Updated: 10/14/2015
SNBL Clinical Pharmacology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women
Wiser Choices in Osteoporosis Trial: The OSTEOPOROSIS CHOICE Decision Aid to Support the Decision to Use or Not Use Bisphosphonates in Postmenopausal Women at Risk of Osteoporotic Fractures.
Status: Enrolling
Updated:  2/1/2016
The Mayo Clinic
mi
from
Rochester, MN
Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women
Wiser Choices in Osteoporosis Trial: The OSTEOPOROSIS CHOICE Decision Aid to Support the Decision to Use or Not Use Bisphosphonates in Postmenopausal Women at Risk of Osteoporotic Fractures.
Status: Enrolling
Updated: 2/1/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Effects of Denosumab on the Pharmacokinetics of Etanercept
The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Clinical Research Facility
mi
from
Duncansville, PA
Effects of Denosumab on the Pharmacokinetics of Etanercept
The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Effects of Denosumab on the Pharmacokinetics of Etanercept
The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Clinical Research Facility
mi
from
Dallas, TX
Effects of Denosumab on the Pharmacokinetics of Etanercept
The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Huntsville, AL
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Tempe, AZ
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Tempe, AZ
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Laguna Woods, CA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Laguna Woods, CA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Mission Viejo, CA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Oceanside, CA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Santa Clarita, CA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Santa Clarita, CA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Upland, CA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Vista, CA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Vista, CA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Denver, CO
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cromwell, CT
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cromwell, CT
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Waterbury, CT
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Newark, DE
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Aventura, FL
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Aventura, FL
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Miami, FL
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Pembroke Pines, FL
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Tampa, FL
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Augusta, GA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Decatur, GA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Chicago, IL
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
South Bend, IN
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
South Bend, IN
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Des Moines, IA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Des Moines, IA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Wichita, KA
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Bangor, ME
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Bangor, ME
Click here to add this to my saved trials